VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED.

Lee, Cecilia S and Kim, Alisa J and Baughman, Douglas and Egan, Catherine and Bailey, Clare and Johnston, Robert L and Natha, Salim and Khan, Rehna and Brand, Christopher and Akerele, Toks and McKibbin, Martin and Downey, Louise and Al-Husainy, Saher and Lee, Aaron Y and Tufail, Adnan (2018) VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED. Retina (Philadelphia, Pa.), 38 (5). pp. 951-956. ISSN 1539-2864. This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs

Full text not available from this repository.
Official URL: https://journals.lww.com/retinajournal/Abstract/20...

Abstract

PURPOSE

To assess whether visual benefits exist in switching to aflibercept in patients who have been chronically treated with ranibizumab for neovascular age-related macular degeneration.

METHODS

A multicenter, national, electronic medical record database study was performed. Patients undergoing six continuous monthly ranibizumab injections and then switched to continuous aflibercept were matched to those on continuous ranibizumab therapy. Matching was performed in a 2:1 ratio and based on visual acuity 6 months before and at the time of the switch, and the number of previous ranibizumab injections.

RESULTS

Patients who were switched to aflibercept demonstrated transiently significant improvement in visual acuity that peaked at an increase of 0.9 Early Treatment Diabetic Retinopathy Study letters 3 months after the switch, whereas control patients continued on ranibizumab treatment showed a steady decline in visual acuity. Visual acuity differences between the groups were significant (P < 0.05) at 2, 3, and 5 months after the switch. Beginning at 4 months after the switch, the switch group showed a visual acuity decline similar to the control group.

CONCLUSION

Transient, nonsustained improvement in visual acuity occurs when switching between anti-vascular endothelial growth factor agents, which may have implications in treating patients on chronic maintenance therapy on one anti-vascular endothelial growth factor medication.

Item Type: Article
Additional Information: This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs
Subjects: WW Eyes. Ophthalmology
Divisions: Ambulatory Care > Ophthalmology
Related URLs:
Depositing User: Mrs Semanti Chakraborty
Date Deposited: 16 Jul 2018 15:53
Last Modified: 16 Jul 2018 15:53
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1698

Actions (login required)

View Item View Item